Sartorius Aktiengesellschaft (SARTF) Income Statement Analysis

See more : Hokkaido Electric Power Company, Incorporated (9509.T) Income Statement Analysis – Financial Results

Complete financial analysis of Sartorius Aktiengesellschaft (SARTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sartorius Aktiengesellschaft, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

Applied Materials, Inc. (0R1A.L) Income Statement Analysis – Financial Results
Bank of Nanjing Co., Ltd. (601009.SS) Income Statement Analysis – Financial Results
Solid Försäkringsaktiebolag (publ) (SFAB.ST) Income Statement Analysis – Financial Results
Rathbones Group Plc (RAT.L) Income Statement Analysis – Financial Results
NexOptic Technology Corp. (NXO.V) Income Statement Analysis – Financial Results

Sartorius Aktiengesellschaft (SARTF)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.sartorius.com

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	3.40B	4.17B	3.45B	2.34B	1.83B	1.57B	1.40B	1.30B	1.11B	891.17M	887.27M	845.71M	733.10M	659.32M	602.08M	611.62M	589.03M	521.05M	484.30M	467.56M	442.26M	476.53M
Cost of Revenue	1.83B	1.98B	1.61B	1.13B	885.81M	762.43M	697.73M	668.50M	563.01M	461.55M	457.62M	425.72M	375.66M	343.16M	329.80M	325.27M	316.35M	275.38M	258.16M	251.77M	238.27M	268.24M
Gross Profit	1.57B	2.20B	1.84B	1.21B	941.16M	803.60M	706.84M	631.80M	551.75M	429.62M	429.65M	420.00M	357.44M	316.16M	272.29M	286.35M	272.68M	245.68M	226.15M	215.79M	203.99M	208.29M
Gross Profit Ratio	46.15%	52.61%	53.31%	51.63%	51.51%	51.31%	50.32%	48.59%	49.50%	48.21%	48.42%	49.66%	48.76%	47.95%	45.22%	46.82%	46.29%	47.15%	46.70%	46.15%	46.12%	43.71%
Research & Development	170.80M	177.80M	139.88M	108.43M	95.59M	78.20M	68.78M	59.42M	52.51M	50.41M	53.77M	48.12M	44.31M	42.63M	40.16M	43.92M	41.53M	35.53M	32.70M	27.59M	25.23M	23.00M
General & Administrative	214.30M	200.50M	165.05M	125.94M	107.21M	94.24M	83.30M	74.71M	65.74M	58.28M	52.87M	49.13M	41.65M	39.06M	37.59M	38.41M	35.38M	34.18M	36.31M	42.77M	43.79M	46.84M
Selling & Marketing	634.40M	628.50M	580.68M	438.72M	369.68M	329.83M	296.84M	256.61M	225.89M	200.22M	207.09M	187.50M	159.52M	148.53M	137.46M	150.23M	142.59M	123.48M	-118.79M	-114.10M	-115.21M	-121.76M
SG&A	848.70M	829.00M	745.72M	564.66M	476.89M	424.07M	380.13M	331.32M	291.63M	258.50M	259.96M	236.63M	201.16M	187.58M	175.04M	188.64M	177.96M	157.65M	-82.48M	-71.33M	-71.42M	-74.92M
Other Expenses	4.40M	13.50M	19.99M	21.99M	5.18M	-1.67M	-35.52M	-27.45M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	1.02B	1.02B	905.59M	695.08M	577.66M	502.98M	443.88M	384.13M	340.10M	299.47M	305.37M	294.52M	264.29M	239.07M	248.40M	229.52M	223.35M	191.52M	182.49M	183.28M	189.31M	194.77M
Cost & Expenses	2.88B	3.00B	2.52B	1.82B	1.46B	1.27B	1.14B	1.05B	903.10M	761.02M	762.99M	720.24M	639.95M	582.23M	578.20M	554.79M	539.70M	466.90M	440.65M	435.05M	427.58M	463.01M
Interest Income	4.60M	1.00M	396.00K	414.00K	341.00K	499.00K	340.00K	233.00K	549.00K	118.00K	191.00K	570.00K	801.00K	359.00K	456.00K	942.00K	1.04M	235.00K	8.63M	4.83M	5.40M	6.45M
Interest Expense	144.90M	35.20M	26.92M	22.27M	15.95M	14.51M	14.55M	9.53M	9.73M	13.16M	11.71M	12.37M	14.90M	7.17M	14.07M	24.60M	12.36M	3.29M	152.00K	175.00K	254.00K	442.00K
Depreciation & Amortization	342.30M	287.10M	231.18M	180.00M	132.72M	113.37M	98.36M	75.71M	58.85M	54.91M	47.73M	40.63M	32.81M	31.85M	33.45M	29.59M	27.36M	19.21M	18.83M	22.27M	23.02M	22.74M
EBITDA	873.10M	1.42B	966.97M	704.06M	488.53M	405.13M	349.29M	321.32M	254.15M	185.83M	171.49M	163.76M	123.89M	104.29M	54.32M	81.04M	83.29M	68.37M	57.42M	50.30M	32.80M	30.70M
EBITDA Ratio	25.71%	34.09%	28.03%	30.14%	26.74%	25.87%	24.87%	24.71%	22.80%	20.85%	19.33%	19.36%	17.29%	16.41%	9.60%	13.25%	13.29%	13.84%	11.18%	10.76%	7.42%	6.44%
Operating Income	543.20M	1.14B	735.80M	523.47M	355.95M	291.76M	250.93M	245.62M	195.30M	130.92M	123.76M	123.13M	93.95M	76.36M	24.34M	51.45M	50.95M	52.88M	35.33M	28.03M	9.78M	7.96M
Operating Income Ratio	16.00%	27.21%	21.33%	22.41%	19.48%	18.63%	17.87%	18.89%	17.52%	14.69%	13.95%	14.56%	12.82%	11.58%	4.04%	8.41%	8.65%	10.15%	7.30%	5.99%	2.21%	1.67%
Total Other Income/Expenses	-157.30M	42.40M	-67.40M	-86.58M	-60.37M	-21.06M	-64.37M	-43.56M	-22.92M	-12.67M	-20.55M	-28.98M	-27.30M	-9.36M	-43.94M	-23.66M	-17.95M	-7.01M	-152.00K	-175.00K	-254.00K	-442.00K
Income Before Tax	385.90M	1.18B	668.42M	446.68M	303.18M	270.70M	198.59M	204.11M	172.38M	96.29M	101.51M	96.49M	79.05M	62.72M	10.27M	26.85M	41.22M	45.87M	35.18M	27.86M	9.53M	7.52M
Income Before Tax Ratio	11.36%	28.31%	19.38%	19.12%	16.59%	17.29%	14.14%	15.70%	15.46%	10.81%	11.44%	11.41%	10.78%	9.51%	1.71%	4.39%	7.00%	8.80%	7.26%	5.96%	2.15%	1.58%
Income Tax Expense	95.90M	268.60M	241.45M	125.21M	84.43M	73.22M	39.26M	59.10M	54.99M	32.38M	30.87M	32.24M	26.25M	22.03M	6.24M	10.57M	10.92M	16.85M	13.15M	12.62M	5.03M	3.07M
Net Income	205.20M	913.10M	426.98M	321.47M	218.74M	141.34M	114.73M	102.93M	126.30M	48.49M	52.42M	48.51M	41.56M	31.02M	975.00K	12.36M	30.13M	29.02M	22.11M	15.23M	4.36M	3.99M
Net Income Ratio	6.04%	21.87%	12.38%	13.76%	11.97%	9.03%	8.17%	7.92%	11.33%	5.44%	5.91%	5.74%	5.67%	4.70%	0.16%	2.02%	5.12%	5.57%	4.57%	3.26%	0.99%	0.84%
EPS	3.00	13.35	6.24	4.70	3.20	2.07	1.67	1.50	1.85	0.71	0.77	0.71	0.61	0.46	0.01	0.18	0.44	0.43	0.33	0.22	0.07	0.06
EPS Diluted	3.00	13.35	6.24	4.70	3.20	2.07	1.67	1.50	1.85	0.71	0.77	0.71	0.61	0.46	0.01	0.18	0.44	0.43	0.33	0.22	0.07	0.06
Weighted Avg Shares Out	68.42M	68.42M	68.42M	68.42M	68.39M	68.39M	68.39M	68.39M	68.19M	68.19M	68.19M	68.19M	68.19M	68.19M	68.19M	68.18M	68.18M	68.19M	68.19M	68.18M	68.18M	68.18M
Weighted Avg Shares Out (Dil)	68.42M	68.42M	68.42M	68.42M	68.39M	68.39M	68.39M	68.39M	68.19M	68.19M	68.19M	68.19M	68.19M	68.19M	68.19M	68.18M	68.18M	68.19M	68.19M	68.18M	68.18M	68.18M

Sartorius Aktiengesellschaft (SARTF) Q3 2024 Earnings Call Transcript

October 17, 2024seekingalpha.com

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q3 2024 Earnings Conference Call October 17, 2024 7:00 AM ET Company Participants Joachim Kreuzburg - Chairman René Fáber - Chief Executive Officer Florian Funck - Chief Financial Officer Conference Call Participants Zain Ebrahim - JPMorgan Charles...

Sartorius Aktiengesellschaft (SARTF) Q1 2024 Earnings Call Transcript

April 18, 2024seekingalpha.com

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q1 2024 Earnings Conference Call April 18, 2024 7:00 AM ET Corporate Participants Dr. Joachim Kreuzburg - Chairman René Fáber - Chief Executive Officer Florian Funck - Chief Financial Officer Conference Call Participants Vineet Agrawal - Citi...

SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know

February 20, 2024zacks.com

SARTORIUS (SARTF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript

January 26, 2024seekingalpha.com

Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript

10 stocks for investors looking for ‘wonderful companies at a fair price'

January 20, 2024marketwatch.com

As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.

SARTORIUS (SARTF) Q3 Earnings Lag Estimates

October 19, 2023zacks.com

SARTORIUS (SARTF) came out with quarterly earnings of $1.13 per share, missing the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $2.47 per share a year ago.

Sartorius Aktiengesellschaft (SARTF) Q2 2023 Earnings Call Transcript

July 21, 2023seekingalpha.com

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q2 2023 Earnings Conference Call July 21, 2023 9:30 AM ET Company Participants Joachim Kreuzburg - Chairman of the Executive Board and Chief Executive Officer Rainer Lehmann - Chief Financial Officer René Fáber - Head of the...